Pharma Pulse: The Oral GLP-1 Battle and GSK’s Billion-Dollar Breath of Fresh Air

Feb 27, 10:30 AM
Headliner
Share
Subscribe
In today’s Pharma Pulse, Eli Lilly’s orforglipron shows superior blood sugar control over oral semaglutide, while GSK secures a $950 million acquisition of 35Pharma.
Share
Subscribe
Next
Cybersecurity and AI in the Era of Home-Based Care Logistics
Top episodes
Overcoming Supply Chain Challenges
by Pharma Pulse
Incorporating AI into Commercialization Plans
by Pharma Pulse
The Capabilities of a 3PL Provider
by Pharma Pulse